Vera Therapeutics Net Worth
Vera Therapeutics Net Worth Breakdown | VERA |
Vera Therapeutics Net Worth Analysis
Vera Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Vera Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Vera Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Vera Therapeutics' net worth analysis. One common approach is to calculate Vera Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Vera Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Vera Therapeutics' net worth. This approach calculates the present value of Vera Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Vera Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Vera Therapeutics' net worth. This involves comparing Vera Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Vera Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Vera Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Vera Therapeutics' net worth research are outlined below:
| Vera Therapeutics generated a negative expected return over the last 90 days | |
| Vera Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (95.99 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Vera Therapeutics currently holds about 131.93 M in cash with (92.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.86. | |
| Vera Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 92.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from investing.com: Vera Therapeutics adds Christy Oliger to board |
Vera Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Vera Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Vera Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Vera Therapeutics Target Price Consensus
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Vera target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Vera Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 10 | Strong Buy |
Most Vera analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Vera stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Vera Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationVera Therapeutics Target Price Projection
Vera Therapeutics' current and average target prices are 35.53 and 21.67, respectively. The current price of Vera Therapeutics is the price at which Vera Therapeutics is currently trading. On the other hand, Vera Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Vera Therapeutics Market Quote on 18th of June 2024
Target Price
Analyst Consensus On Vera Therapeutics Target Price
Know Vera Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vera Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vera Therapeutics backward and forwards among themselves. Vera Therapeutics' institutional investor refers to the entity that pools money to purchase Vera Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Holocene Advisors, Lp | 2024-03-31 | 1.2 M | Point72 Asset Management, L.p. | 2024-03-31 | 1.2 M | Pictet Asset Manangement Sa | 2024-03-31 | 1 M | Geode Capital Management, Llc | 2024-03-31 | 961.3 K | Woodline Partners Lp | 2024-03-31 | 947.1 K | Adage Capital Partners Gp Llc | 2024-03-31 | 837.2 K | Altium Capital Management, Lp | 2024-03-31 | 710 K | Orbimed Advisors, Llc | 2024-03-31 | 675.9 K | Polar Capital Holdings Plc | 2024-03-31 | 675 K | Venbio Select Advisor Llc | 2024-03-31 | 5.3 M | Blackrock Inc | 2024-03-31 | 3.3 M |
Follow Vera Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.97 B.Market Cap |
|
Project Vera Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.55) | (0.57) | |
| Return On Capital Employed | (0.67) | (0.70) | |
| Return On Assets | (0.55) | (0.57) | |
| Return On Equity | (0.94) | (0.90) |
When accessing Vera Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Vera Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Vera Therapeutics' profitability and make more informed investment decisions.
The data published in Vera Therapeutics' official financial statements typically reflect Vera Therapeutics' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Vera Therapeutics' quantitative information. For example, before you start analyzing numbers published by Vera accountants, it’s essential to understand Vera Therapeutics' liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Please note, the presentation of Vera Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vera Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Vera Therapeutics' management manipulating its earnings.
Evaluate Vera Therapeutics' management efficiency
Vera Therapeutics has return on total asset (ROA) of (0.2025) % which means that it has lost $0.2025 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3689) %, meaning that it created substantial loss on money invested by shareholders. Vera Therapeutics' management efficiency ratios could be used to measure how well Vera Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of June 18, 2024, Return On Tangible Assets is expected to decline to -0.57. In addition to that, Return On Capital Employed is expected to decline to -0.7. At present, Vera Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 10.5 M, whereas Total Assets are forecasted to decline to about 99.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.38 | 2.50 | |
| Tangible Book Value Per Share | 2.38 | 2.50 | |
| Enterprise Value Over EBITDA | (6.40) | (6.72) | |
| Price Book Value Ratio | 6.46 | 6.78 | |
| Enterprise Value Multiple | (6.40) | (6.72) | |
| Price Fair Value | 6.46 | 6.78 | |
| Enterprise Value | 664.9 M | 423.8 M |
The analysis of Vera Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Vera Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Vera Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Return On Equity (0.37) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vera Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vera Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vera Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vera Therapeutics Corporate Filings
8K | 12th of June 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 11th of June 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
F4 | 17th of May 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 10th of May 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Vera Therapeutics Earnings Estimation Breakdown
The calculation of Vera Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Vera Therapeutics is estimated to be -0.56 with the future projection ranging from a low of -0.65 to a high of -0.48. Please be aware that this consensus of annual earnings estimates for Vera Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.65 Lowest | Expected EPS | -0.48 Highest |
Vera Therapeutics Earnings Projection Consensus
Suppose the current estimates of Vera Therapeutics' value are higher than the current market price of the Vera Therapeutics stock. In this case, investors may conclude that Vera Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Vera Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2024 | Current EPS (TTM) | |
| 0 | 78.41% | -0.56 | -0.56 | -2.01 |
Vera Therapeutics Earnings History
Earnings estimate consensus by Vera Therapeutics analysts from Wall Street is used by the market to judge Vera Therapeutics' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Vera Therapeutics' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Vera Therapeutics Quarterly Gross Profit |
|
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Vera Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Vera Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Vera Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Vera Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Vera Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Vera Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Vera Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Vera Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Vera Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Vera Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-15 | 2024-03-31 | -0.53 | -0.56 | -0.03 | 5 | ||
2024-03-04 | 2023-12-31 | -0.51 | -0.6 | -0.09 | 17 | ||
2023-11-09 | 2023-09-30 | -0.53 | -0.45 | 0.08 | 15 | ||
2023-08-10 | 2023-06-30 | -0.69 | -0.46 | 0.23 | 33 | ||
2023-05-11 | 2023-03-31 | -0.6 | -0.8 | -0.2 | 33 | ||
2023-03-28 | 2022-12-31 | -0.9 | -1.18 | -0.28 | 31 | ||
2022-11-09 | 2022-09-30 | -0.72 | -0.91 | -0.19 | 26 | ||
2022-08-10 | 2022-06-30 | -0.72 | -0.55 | 0.17 | 23 | ||
2022-05-16 | 2022-03-31 | -0.67 | -0.71 | -0.04 | 5 | ||
2022-03-24 | 2021-12-31 | -0.46 | -0.79 | -0.33 | 71 | ||
2021-11-10 | 2021-09-30 | -0.59 | -0.36 | 0.23 | 38 | ||
2021-08-16 | 2021-06-30 | -0.39 | -0.33 | 0.06 | 15 | ||
2021-06-24 | 2021-03-31 | -1.94 | -12.23 | -10.29 | 530 |
Vera Therapeutics Corporate Management
| Tad Thomas | Sr Manufacturing | Profile | |
| Marshall MD | President, Founder | Profile | |
| Julien JD | VP Legal | Profile | |
| Joanne Curley | Chief Officer | Profile | |
| Kerry MD | Senior Affairs | Profile | |
| Joseph MBA | Senior Officer | Profile | |
| Robert MD | Chief Officer | Profile |
Additional Information and Resources on Investing in Vera Stock
When determining whether Vera Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vera Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vera Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vera Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vera Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Vera Stock refer to our How to Trade Vera Stock guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vera Therapeutics. If investors know Vera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vera Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.01) | Return On Assets (0.20) | Return On Equity (0.37) |
The market value of Vera Therapeutics is measured differently than its book value, which is the value of Vera that is recorded on the company's balance sheet. Investors also form their own opinion of Vera Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vera Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vera Therapeutics' market value can be influenced by many factors that don't directly affect Vera Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vera Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vera Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vera Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.